末梢動脈疾患および2型糖尿病患者を対象に、セマグルチドと呼ばれる薬剤とプラセボを比較する研究

基本情報

NCT ID

NCT04560998

ステータス

完了

試験のフェーズ

第3相

試験タイプ

介入

目標被験者数

792

治験依頼者名

Novo Nordisk A/S

概要

This study is done to see if semaglutide has an effect on walking ability compared with placebo (dummy medicine) in people with peripheral arterial disease (PAD) and type 2 diabetes. Participants will either get semaglutide or placebo ("dummy") medicine - which treatment participants get is decided by chance. Semaglutide is a medicine for type 2 diabetes that can be prescribed by doctors in some countries. Participants will get the study medicine (semaglutide or placebo) in a pre-filled pen for injection. Participants must inject it once a week into the stomach area, thigh, or upper arm, at any time of the day. The study will last for about 59 weeks. Participants will have 8 clinic visits and 1 phone call with the study doctor. At some clinic visits, participants will have blood tests. At some visits participants will also do a treadmill test to measure how far they can walk. Women cannot take part if pregnant, breast-feeding or planning to become pregnant during the study period.

対象疾患

介入

依頼者（Sponsor）

実施施設 (12)